Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05667727
Other study ID # R2016
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 15, 2023
Est. completion date June 1, 2025

Study information

Verified date April 2024
Source Oman Medical Speciality Board
Contact Adnan Al-Rawahi, Resident
Phone 00968 95576483
Email r2016@resident.omsb.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Our study aiming to look in improvement of Pediatric Respiratory Assessment Measure (PRAM) score as a primary outcome. The secondary outcomes involving the need for second step management, need for admission and possible side effects. It's double blinded randomized control study comparing Nebulized Epinephrine with standard treatment (salbutamol + Ipratropium) versus the standard treatment only in pediatric patient. A pilot study will be conducted before to detect the sample size required and data will be collected at deferent interval post treatment targeting intension to treat for analysis.


Description:

Because there are no previous studies with the same methodology found, pilot study will be conducted to estimate the sample size. Patients who are eligible to be enrolled in the study will be randomized into two group (after receiving the standard of care, 3 back to back nebulization (salbutamol and ipratropium bromide)) , the experimental group will be given epinephrine (1ml of 1:1000) as nebulization and the control group will receive salbutamol nebulization as 4th nebulization. PRAM score with calculated before and at 60, 80, 100 min after the treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date June 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 13 Years
Eligibility - Inclusion Criteria: - Pediatric age group 3 - 12 years - known to have asthma - Initial PRAM Score showed moderate to severe asthma exacerbation - Exclusion Criteria: - History of lung or upper airway disease other than asthma: - bronchiolitis, anaphylaxis, pertussis, vocal cord dysfunction, foreign body aspiration, bronchopulmonary dysplasia, cystic fibrosis and lower airway mass effects - History of congenital heart disease or cardiac arrhythmia or heart failure. - Known hypertension - Impending respiratory failure (Decreasing mental status, Respiratory fatigue, Impending respiratory arrest, Hypoxemia (pO2 < 60 mmHg), pCO2 could be normal or high) - Allergy or hypersensitivity to epinephrine - Patient/Parents refusal to participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
nebulized epinephrine
we are using 1:1000 epinephrine into nebulization form
Salbutamol
Patient will receive salbutamol as 4th nebulization.

Locations

Country Name City State
Oman Royal Hospital Muscat

Sponsors (1)

Lead Sponsor Collaborator
Oman Medical Speciality Board

Country where clinical trial is conducted

Oman, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in pediatric respiratory assessment measure (PRAM) score treating physician will calculate the PRAM score before and immediately after the intervention by 20 mins, if there is no change in PRAM score or the case worsen, candidate will receive further treatment, but if he/she improved, will be assessed in the second interval. at (60) mints
Primary change in pediatric respiratory assessment measure (PRAM) score immediately after the intervention by 40 mins, candidate will be assessed, calculating the PRAM score again, and decide he/she will need further treatment or to continue observation. at (80) mints
Primary change in pediatric respiratory assessment measure (PRAM) score immediately after the intervention by 90 mins, candidate will be assessed again, calculating the PRAM score and decide about if he will need further treatment or no.
Total observation will be almost 2 hours in order to look for other outcome as well.
at (100) mints
Secondary Emergency Department (ED) length of stay "during the assessment", after the exposure
This outcome will be decided upon each reassessment intervals, at any time during assessment if there is no change in PRAM score or worsening patient will receive further treatment as decided before and his enrollment in the study will be ended here.
from the randomization up to 4 hours
Secondary The rate for admission "during the assessment"
this will be determined at the disposal plan for each candidate from the emergency department, either admission or discharge home.
from the randomization up to 4 hours
Secondary rate of any side effect of nebulized epinephrine "during the assessment"
Each candidate will be assessed throughout the enrolment in the study, starting from the administration of the medication till 2 hours post exposure.
from the randomization up to 4 hours
Secondary The need for respiratory support (O2, Non-invasive ventilation, intubation) "during assessment" from the randomization to the disposal time
Secondary The rate of revisit to Emergency Department within 72 hours of the index visit "after discharge" Till 72 hours post discharge
See also
  Status Clinical Trial Phase
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Recruiting NCT05734261 - Forced Oscillations Technique During a Metacholine Test in Children N/A
Recruiting NCT06044051 - Dynamics of the Upper and Lower Airway Respiratory Microbiomes Associated With Severe Infant Asthma N/A
Completed NCT04896502 - Effectiveness of Telemedicine Home Assessments for Identification and Reduction of Asthma Triggers N/A
Completed NCT03503812 - Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches N/A
Recruiting NCT06003569 - Reducing Asthma Attacks in Disadvantaged School Children With Asthma N/A
Not yet recruiting NCT05902702 - Isotonic Saline for Children With Bronchiolitis N/A
Not yet recruiting NCT05547477 - Continuous EMG Measurements in Children With Asthma During Sleep
Completed NCT04388098 - Oral Health Status of Asthmatic Children
Terminated NCT03586544 - Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity Phase 4
Recruiting NCT04821908 - Consequences of COVID 19 Pandemic on Childhood Asthma
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Enrolling by invitation NCT06239844 - Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English N/A
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Not yet recruiting NCT05974917 - Serious gaMes as Emerging E-health Interventions for Young People With neurologicaL or rEspiratory disoRders
Recruiting NCT05366309 - Performance and Adherence in Children Using Spacers N/A
Completed NCT05684926 - COVID-19 Pandemic Asthma Child Telerehabilitation Yoga N/A
Recruiting NCT04166344 - A mHealth Intervention to Improve Symptom Control in Children and Adolescents With Difficult-to-control Asthma N/A
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT03907410 - The Tailored Adherence Incentives for Childhood Asthma Medications (TAICAM) Trial N/A